SEC Comment Letter 0000000000-23-000868 to NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091) (NRSN)
NeuroSense Therapeutics Ltd. (NRSN, NRSNW) (CIK 0001875091)
Date: Jan. 26, 2023 · CIK: 0001875091 · Accession: 0000000000-23-000868
AI Filing Summary & Sentiment
File numbers found in text: 333-269306
Letter
United States securities and exchange commission logo January 26, 2023 Alon Ben-Noon Chief Executive Officer NeuroSense Therapeutics Ltd. 11 Ha-Menofim Street, Building B Herzliya 4672562 Israel Re:NeuroSense Therapeutics Ltd. Registration Statement on Form F-3 Filed January 19, 2023 File No. 333-269306 Dear Alon Ben-Noon: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Sarah C. Griffiths
Show Raw Text
United States securities and exchange commission logo
January 26, 2023
Alon Ben-Noon
Chief Executive Officer
NeuroSense Therapeutics Ltd.
11 Ha-Menofim Street, Building B
Herzliya 4672562 Israel
Re:NeuroSense Therapeutics Ltd.
Registration Statement on Form F-3
Filed January 19, 2023
File No. 333-269306
Dear Alon Ben-Noon:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Sarah C. Griffiths